GLP-1 Manufacturer Rebate & Savings Programs: Complete Guide (2026)
NovoCare, LillyDirect, savings cards, patient assistance, TrumpRx, and Medicare coverage. Every legitimate way to lower your GLP-1 cost—and which programs have the strongest savings.
The strongest manufacturer rebate programs are the Novo Nordisk Savings Card and Lilly Savings Card, which can reduce copays to $25/month or less for commercially insured patients. For uninsured patients, LillyDirect ($299–$449/month for Zepbound) and NovoCare ($349/month for Wegovy) offer the deepest direct-from-manufacturer discounts. Patient assistance programs from both companies can provide medications free of charge for qualifying low-income patients.
How GLP-1 Savings Programs Work
There are five distinct categories of manufacturer savings programs for GLP-1 medications, and they serve very different populations. Understanding which ones you qualify for is the first step to finding the lowest price.
Savings cards / copay cards reduce your out-of-pocket cost if you have commercial insurance. They don't change the medication's price—they cover the gap between your insurance payment and what the manufacturer thinks you should pay. These are the most commonly advertised programs.
Direct-to-consumer pharmacy programs (LillyDirect, NovoCare Pharmacy) sell the medication at a fixed cash price, bypassing retail pharmacies and PBMs. These are available to uninsured patients or those who prefer to pay cash.
Patient assistance programs (PAPs) provide free medication to patients who meet income requirements. These are underused and potentially the most valuable program for qualifying patients.
TrumpRx is a government-facilitated direct pricing portal launched in February 2026 that directs patients to manufacturer websites at negotiated prices.
Medicare/Medicaid programs are the newest pathway, with the Medicare GLP-1 Bridge launching mid-2026 at approximately $50/month for qualifying beneficiaries.
Novo Nordisk Programs (Wegovy, Ozempic)
Wegovy & Ozempic Savings Card
Eligible commercially insured patients pay as little as $25/month for Wegovy or Ozempic, with savings up to $100/month applied at the pharmacy. This is the single strongest rebate program available for GLP-1 medications.
NovoCare Pharmacy (Direct Cash-Pay)
Novo Nordisk's direct-to-patient pharmacy sells Wegovy and Ozempic at fixed cash prices, shipped to your door. This bypasses retail pharmacy markups and doesn't require insurance. However, government insurance beneficiaries are excluded from this pricing even if they choose to pay cash.
Novo Nordisk Patient Assistance Program
The most underused program. Qualifying patients receive Wegovy or Ozempic free of charge. This is available to uninsured patients and even some Medicare patients who've been denied coverage, provided they meet income thresholds.
Eli Lilly Programs (Zepbound, Mounjaro)
Zepbound & Mounjaro Savings Card
Commercially insured patients can pay as little as $25/month with savings up to $100/month. Limited to 13 fills per year. This program alone can save insured patients over $12,000 annually compared to list price.
LillyDirect (Zepbound Self Pay Journey Program)
Eli Lilly's direct-to-patient program for Zepbound offers single-dose vials at 60–70% below list price. The Journey Program provides additional savings for patients who refill within 45 days. This is the cheapest path to FDA-approved tirzepatide without insurance.
Lilly Cares Patient Assistance Program
Free Mounjaro or Zepbound for qualifying low-income patients. Lilly Cares has a more generous income threshold than the Novo Nordisk PAP, accepting patients up to 300% of the federal poverty level.
TrumpRx & Medicare Coverage (New for 2026)
Two major government-facilitated programs are reshaping GLP-1 access in 2026.
TrumpRx Direct Pricing
Launched February 5, 2026, TrumpRx.gov is a portal that directs patients to manufacturer websites where they can purchase medications at negotiated prices. For GLP-1s, starter doses are available at approximately $350/month, which is close to existing LillyDirect and NovoCare pricing. The practical savings over existing direct programs are modest ($50–100/month), but TrumpRx consolidates the options in one place and signals ongoing government pressure on pricing.
Medicare GLP-1 Bridge
Starting mid-2026, Medicare will cover certain GLP-1 medications for obesity for the first time. Qualifying beneficiaries (estimated at approximately 10% of Medicare enrollees based on BMI and comorbidity criteria) will pay roughly $50/month. This is a landmark change for the 65+ population, who have been largely excluded from manufacturer savings programs due to federal anti-kickback laws.
Patients on Medicare, Medicaid, TRICARE, or VA benefits are excluded from manufacturer savings cards AND from NovoCare/LillyDirect self-pay pricing. The only manufacturer options available to these patients are patient assistance programs (income-qualified) and the upcoming Medicare GLP-1 Bridge. Compounded medications remain available to this population through telehealth providers.
Which Program Has the Strongest Savings?
| Program | Your Monthly Cost | Who Qualifies | Strength |
|---|---|---|---|
| Patient Assistance (PAP) | $0 | Low-income, uninsured/underinsured | ★★★★★ |
| Savings Card + Insurance | $0–$25 | Commercially insured with coverage | ★★★★★ |
| Medicare Bridge (mid-2026) | ~$50 | Medicare Part D, qualifying BMI | ★★★★ |
| NovoCare Wegovy (intro) | $199 | Cash-pay, non-government insurance | ★★★ |
| LillyDirect Zepbound | $299–$449 | Cash-pay, non-government insurance | ★★★ |
| NovoCare Wegovy (standard) | $349 | Cash-pay, non-government insurance | ★★ |
| TrumpRx | ~$350 | All patients (redirects to manufacturer) | ★★ |
When Manufacturer Programs Don't Work: Compounded Alternatives
Manufacturer programs leave significant gaps. If you're on government insurance (excluded from savings cards and direct programs), if your commercial plan doesn't cover GLP-1s (savings cards only supplement existing coverage, they don't create it), or if the income threshold for PAPs is too low for your situation, compounded GLP-1 medications through telehealth providers may be your most affordable option.
Compounded semaglutide and tirzepatide from licensed telehealth providers typically cost $149–$399/month with no insurance requirements, no income documentation, and no government insurance exclusions.
Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Patients should discuss the risks and benefits with their healthcare provider before use.
How to Stack Savings Programs
Some patients can layer multiple programs together, though options are limited. The savings card can be used with commercial insurance at most retail pharmacies. If your insurance covers the medication and you apply the savings card, your total out-of-pocket can drop to $0–$25/month. However, savings cards cannot be combined with government insurance, and cash-pay purchases through LillyDirect or NovoCare do not count toward your insurance deductible or out-of-pocket maximum.
HSA and FSA accounts can typically be used for all GLP-1 purchases—including telehealth consultations and compounded medications—when prescribed for a qualifying medical condition. Verify with your specific plan administrator before submitting.
Ready to Compare Your Options?
See all GLP-1 providers with transparent pricing, side by side.
Compare Providers →